World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0040541446
Reproduction Date:

Title: Nsi-189  
Author: World Heritage Encyclopedia
Language: English
Subject: Esketamine, Nootropics, SIB-1553A, TC-1827, Adafenoxate
Collection: Antidepressants, Nicotinamides, Nootropics
Publisher: World Heritage Encyclopedia


Systematic (IUPAC) name
Clinical data
  • US: N (Not classified yet)
Legal status
  • Unscheduled
Routes of
ATC code None
PubChem CID:
Chemical data
Formula C22H30N4O
Molecular mass 366.4998 g/mol

NSI-189 is an experimental drug being studied by Neuralstem, Inc.[1] Research into NSI-189 has been funded by the Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH) for the treatment of major depressive disorder.[2]


  • Pharmacology 1
  • Clinical trials 2
  • See also 3
  • References 4


NSI-189 has been shown to increase the hippocampal volume of adult mice by 20%,[3] and has been shown to stimulate neurogenesis of human hippocampal stem cells in vitro and in vivo. The hippocampus is responsible for the consolidation of information from short-term memory to long-term memory, along with spatial navigation, and is also involved in regulation of mood.[2][4][5]

Clinical trials

NSI-189 successfully completed a phase 1 clinical trial in 2011 where it was administered to 41 healthy volunteers.[6]

A phase 1b clinical trial for treating major depressive disorder in 24 patients started in 2012 and completed in July 2014.[7][8] The study suggests that there were improvements in the patients' condition when the doses were 40/80 mg per day, but no significant improvements were seen for a higher dosage of 120 mg/day.

Neuralstem intends to pursue further clinical trials for a variety of neurological conditions, including major depressive disorder, traumatic brain injury, Alzheimer's disease, post-traumatic stress disorder,[2] stroke, and natural cognitive and memory decline in aging.[3]

See also


  1. ^ PubChem 50922681
  2. ^ a b c FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder
  3. ^ a b Why Neuralstem Could Provide A 10x Return
  4. ^ The Pill That Could Cure Depression by Growing Your Brain
  5. ^ Compositions to effect neuronal growth
  6. ^ Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189
  7. ^ Multiple-Dose Pharmacokinetics (PK), and Pharmacodynamic (PD) Effect of NSI-189 Phosphate in Depression Patient Subjects
  8. ^ [1]

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.